Novo Nordisk nabs $1.075 billion obesity specialist Inversago

10 August 2023
novo_nordisk_2021_hq

Danish drugmaker Novo Nordisk (NOV: N) is emerging alongside Eli Lilly (NYSE: LLY) as an early frontrunner in the market for obesity treatments.

The company has secured this leadership thanks to its GLP-1 agonist Wegovy (semaglutide), and it is hopeful that its pipeline will maintain this position - an effort aided by its acquisition of Inversago Pharma for up to $1.075 billion in cash if certain development and commercial milestones are achieved.

Inversago Pharma is a private, Montreal, Canada-based developer of CB1 receptor-based therapies for the potential treatment of obesity, diabetes and complications associated with metabolic disorders.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical